Ann: Ceasing to be a substantial holder, page-47

Hi @ralom, I got a straight bat answer I.e Invex directors are not financial advisers, but the business presents good EV when compared to other biotechs at a similar stage of development. No different from what’s been presented to the market. The messaging is plain vanilla at the moment and I respect that. There’s no pumping - it’s just facts. Long run this share will do well. Market cap is ~$60M with $30M in cash. That’s $30M ascribed to the technology which is a bit of a joke but a bargain in my opinion - the 2 cent escrow holders are not frigging helping though.